# A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea

> **NCT01381900** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 678 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Placebo
- **DRUG:** Canagliflozin 100mg
- **DRUG:** Canagliflozin 300mg
- **DRUG:** Metformin
- **DRUG:** Sulphonylurea

## Key facts

- **NCT ID:** NCT01381900
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 678 (ACTUAL)
- **Last updated:** 2014-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01381900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01381900, "A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01381900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*